- Home
- UROY vs HURA Comparison
UROY vs HURA Comparison
Compare UROY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- HURA
- Stock Information
- Founded
- UROY 2017
- HURA 2009
- Country
- UROY Canada
- HURA United States
- Employees
- UROY N/A
- HURA N/A
- Industry
- UROY
- HURA
- Sector
- UROY
- HURA
- Exchange
- UROY Nasdaq
- HURA Nasdaq
- Market Cap
- UROY 294.0M
- HURA 246.9M
- IPO Year
- UROY N/A
- HURA N/A
- Fundamental
- Price
- UROY $2.13
- HURA $4.39
- Analyst Decision
- UROY Strong Buy
- HURA
- Analyst Count
- UROY 2
- HURA 0
- Target Price
- UROY $5.60
- HURA N/A
- AVG Volume (30 Days)
- UROY 2.4M
- HURA 668.3K
- Earning Date
- UROY 12-12-2024
- HURA 02-15-2025
- Dividend Yield
- UROY N/A
- HURA N/A
- EPS Growth
- UROY 256.61
- HURA N/A
- EPS
- UROY 0.03
- HURA N/A
- Revenue
- UROY $27,478,292.00
- HURA N/A
- Revenue This Year
- UROY N/A
- HURA N/A
- Revenue Next Year
- UROY $72.53
- HURA N/A
- P/E Ratio
- UROY $82.15
- HURA N/A
- Revenue Growth
- UROY 31.26
- HURA N/A
- 52 Week Low
- UROY $1.86
- HURA $2.84
- 52 Week High
- UROY $3.76
- HURA $14.60
- Technical
- Relative Strength Index (RSI)
- UROY 31.97
- HURA N/A
- Support Level
- UROY $2.42
- HURA N/A
- Resistance Level
- UROY $2.70
- HURA N/A
- Average True Range (ATR)
- UROY 0.14
- HURA 0.00
- MACD
- UROY -0.03
- HURA 0.00
- Stochastic Oscillator
- UROY 10.94
- HURA 0.00
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.